Binod Dhakal
Medical College of Wisconsin
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Binod Dhakal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07284758 · A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaC4 Therapeutics, Inc. · recruiting · Multiple Myeloma, Relapsed/Refractory Multiple Myeloma · principal investigator
- Ph1NCT07221032 · FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple MyelomaMedical College of Wisconsin · recruiting · Relapse Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph1NCT05976555 · Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory MyelomaMedical College of Wisconsin · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT04835129 · Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaMedical College of Wisconsin · active not recruiting · Multiple Myeloma · principal investigator
- Ph1NCT04355039 · INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple MyelomaMedical College of Wisconsin · withdrawn · Refractory Multiple Myeloma, Relapse Multiple Myeloma · principal investigator
- Ph2NCT04240054 · Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal InsufficiencyMedical College of Wisconsin · recruiting · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:17 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.N Engl J Med · 2023749 citationsRCR 61.8
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.J Clin Oncol · 2022234 citationsRCR 18.1
- Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.Lancet Haematol · 2023157 citationsRCR 14.3
- 45 citationsRCR 22.5
- Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.Blood Adv · 202044 citationsRCR 2.1
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Blood Cancer J · 202435 citationsRCR 4.3
- 31 citationsRCR 6.4
- 30 citationsRCR 1.2
- Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.Clin Cancer Res · 202330 citationsRCR 2.1
- A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.Biol Blood Marrow Transplant · 201927 citationsRCR 0.9